Advertisement

Nephrotoxicity pp 371-375 | Cite as

Sensitivity of in Vitro Ion Accumulation, Gluconeogenesis and other Parameters as Indicators of Cisplatin-Induced Renal Toxicity

  • Charles Litterst
  • Jacqueline H. Smith
  • Mary Ann Smith
  • Marion Copley
  • Jiro Uozumi

Abstract

The kidney is a complex organ which controls the fluid and salt balance, and the homeostasis of numerous other organs. Consequently, the functional integrity of the kidney is of paramount importance in maintaining health. Because of its central role in excretion, the kidney is exposed to high and often prolonged concentrations of most xenobiotics that enter the body. Adverse effects on renal function are produced by a large number of these chemicals, including heavy metals such as mercury and cadmium, and drugs such as aminoglycoside antibiotics and antineoplastic agents. One widely used antineoplastic agent whose dose limiting toxicity is to the kidney is cis-diamminedichloroplatinum-II (cisplatin, cisPt). This drug is a square planar molecule which undergoes a complex spontaneous hydrolysis to yield several uncharacterized metabolites, several of which have the potential of being the ultimate toxicant.

Keywords

Toxicity Mercury Cage Platinum Cadmium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Litterst, CL, JH Smith, MA Smith, J Uozumi, M Copley, Sensitivity of urinary enzymes as indicators of renal toxicity of the anticancer drug cisplatin, Uremia Invest. 9:111 (1985)PubMedGoogle Scholar
  2. 2.
    Smith, JH, MA Smith, CL Litterst, MP Copley, J Uozumi, MR Boyd, Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP and cisplatin at equimolar doses in the Fischer 344 rat,Fund. Appl. Tox., In Press (1987).Google Scholar
  3. 3.
    Smith, MA, JH Smith, CL Litterst, MP Copley, J Uozumi, MR Boyd, In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the F-344 rat, Fund. Appl. Tox. In Press, (1987).Google Scholar
  4. 4.
    Bird, JE, MM Walser, AJ Quebbemann, Protective effect of organic cation transport inhibitors on cis-diamminedichloroplatinum-induced nephrotoxicity, J. Pharmacol. Exptl. Therap. 231:752 (1984).Google Scholar
  5. 5.
    Goldstein, RS, B Noordewier, JT Bond, JB Hook, GH Mayor, cis-Dichloro-diammineplatinum nephrotoxicity:time course and dose response of renal functional impairment,Tox. Appl. Pharmacol. 60:163 (1981).CrossRefGoogle Scholar
  6. 6.
    Nelson, JA, G Santos, BH Herbert, Mechanisms for the renal secretion of cisplatin, Cancer Treat. Rep. 68:849 (1984).PubMedGoogle Scholar
  7. 7.
    Williams, PD, GH Hottendorf, Effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex,Cancer Treat. Rep.69:875 (1985).PubMedGoogle Scholar
  8. 8.
    Guarino, AM, DS Miller, ST Arnold, JB Pritchard, RD Davis, MA Urbanek, TJ Miller, CL Litterst, Platinate toxicity:past, present, and prospects, Cancer Treat. Rep. 63:1475 (1979).PubMedGoogle Scholar
  9. 9.
    Daley-Yates, PT, DCH McBrien, Inhibition of renal ATPase by cisplatin and some biotransformation products, Chem.-Biol. Interact. 40:325 (1982).PubMedCrossRefGoogle Scholar
  10. 10.
    Nechay, BR, SL Neldon, Characteristics of inhibition of human renal adenosine triphosphatases by cisplatin and chloroplatinic acid, Cancer Treat. Rep. 68:1135 (1984).PubMedGoogle Scholar
  11. 11.
    Uozumi, J, CL Litterst, Effect of cisplatin on renal ATPase activity in vivo and in vitro, Cancer Chemother. Pharmacol. 15:93 (1985).PubMedCrossRefGoogle Scholar
  12. 12.
    Aggarwal, SK, MW Whitehouse, C Ramachandran, Ultrastructural effects of cisplatin, In: Cisplatin:Current Status and New Developments (AW Prestayko, ST Crooke, SK Carter, eds) , Academic Press, NY, p. 79, 1980.Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Charles Litterst
    • 1
  • Jacqueline H. Smith
    • 1
  • Mary Ann Smith
    • 1
  • Marion Copley
    • 1
  • Jiro Uozumi
    • 1
  1. 1.Division of Cancer Treatment, National Cancer InstituteNIHBethesdaUSA

Personalised recommendations